Global Tuberculosis (TB) Drugs/Therapeutics Market, 2018-2025 - Key Players are J&J Services, Lupin, Pfizer, Novartis, Macleods Pharmaceuticals, and Otsuka Pharmaceutical
DUBLIN, Aug. 24, 2018 /PRNewswire/ --
The "Tuberculosis (TB) Drugs/Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Active TB, Latent TB), By Therapy (First-Line, Second-Line), By Region, Competitive Landscape, And Segment Forecasts, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.
The global tuberculosis drugs/therapeutics (TB) market size is expected to reach USD 1.38 billion by 2025, registering a CAGR of 5.2% during the forecast period.
Rising prevalence of Multidrug Resistant (MDR) tuberculosis and HIV-tuberculosis co-infection is likely to drive the market during the forecast period. According to WHO, in 2017, the annual incidence of tuberculosis (TB) in India was 2.8 million cases, with an estimated 147,000 multi-drug resistant cases. India has the second highest estimation of HIV-TB co-infection cases per year, i.e., 87,000.
The TB drugs market is expected to witness high growth in the coming years due to development of shorter-regimen drug treatments and availability of private and public funding. The Nix-TB trial currently being conducted by TB Alliance in conjunction with Janssen Pharmaceuticals involves a combination of drugs, pretomanid, linezolid, and bedaquiline, which promises a cure for Extensively Drug Resistant (XDR) form of the disease within 6-9 months.
Apart from competitive dynamics, license agreements among players are providing opportunities for emerging drug manufacturers to grow in this space. In September 2015, Dishman Group received a license agreement from Janssen Pharmaceutica NV, subsidiary of Johnson & Johnson Services, LLC to produce the active pharmaceutical ingredient (API) for the drug Sirturo (bedaquiline), intended for MDR TB treatment. Dishman, apart from being an API supplier for Janssen's novel drug, is now listed as a licensed API manufacturer with the EMA, USFDA, and several Asian regulatory authorities.
Further key findings from the report suggest:
-- Collaborative efforts among international organizations and
pharmaceutical players are spurring drug development and treatment
access, which is expected to propel the growth of the tuberculosis drugs
market
-- In March 2015, a collaboration between the United States Agency for
International Development (USAID) and the Janssen Global Services, LLC
was undertaken to provide the drug bedaquiline free of cost to eligible
MDR-tuberculosis patients
-- Based on disease type, the active tuberculosis drugs segment accounted
for the largest share of 87.3% in 2016. If undiagnosed, latent
tuberculosis has the potential to transform to the active form, which
has led countries in Europe and North America to focus on early
diagnosis and preventive measures
-- Based on therapy type, second-line therapy drugs led the market with a
share of 60.4% in 2016. Rising incidence and higher treatment cost
structure of MDR tuberculosis, coupled with increasing treatment access,
is spurring market growth
-- Regionally, Asia Pacific held a major market share and is expected to
retain its dominance during the forecast period due to high disease
incidence and gradual improvement in patient medication adherence rates
-- Europe is likely to witness significant growth over the next decade due
to high MDR-TB burden, along with improved focus on LTBI treatment drugs
-- Some of the key players in the tuberculosis drugs market are Johnson &
Johnson (J&J) Services, Lupin, Pfizer, Novartis AG, Macleods
Pharmaceuticals Limited, and Otsuka Pharmaceutical Co., Ltd.
Key Topics Covered:
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Drivers Analysis
3.1.1.1 Global plan against drug-resistant TB drives diagnosis and treatment enrollment
3.1.1.2 HIV burden fuels LTBI case counts
3.1.2 Market Restraints Analysis
3.1.2.1 High drug cost
3.1.2.2 Poor regulation and lack of awareness in developing countries
3.2 Penetration & growth prospect mapping
3.3 Tuberculosis Drugs/Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter's
Chapter 4 Tuberculosis Drugs/Therapeutics Market: Therapy Type & Trend Analysis
4.1 Tuberculosis Drugs/Therapeutics Market: Therapy Type Movement Analysis
4.1.1 First-Line Therapy
4.1.2 Second-Line Therapy
Chapter 5 Tuberculosis Drugs/Therapeutics Market: Disease Type & Trend Analysis5
5.1 Latent TB
5.2 Active TB
Chapter 6 Regional Estimates & Trend Analysis
Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
Chapter 8 Market Outlook
8.1 Market Scenario
8.2 Pipeline Analysis
Companies Mentioned
-- Johnson & Johnson Services, LLC
-- Lupin
-- Novartis AG
-- Macleods Pharmaceuticals Ltd.
-- Otsuka Pharmaceutical Co., Ltd.
-- Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/g44nvn/global?w=5
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content with multimedia:http://www.prnewswire.com/news-releases/global-tuberculosis-tb-drugstherapeutics-market-2018-2025---key-players-are-jj-services-lupin-pfizer-novartis-macleods-pharmaceuticals-and-otsuka-pharmaceutical-300702065.html
SOURCE Research and Markets
